Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of androgen deprivation therapy with or without prostate radiotherapy and with or without abiraterone acetate plus prednisone in metastatic hormone-naive prostate cancer
2012-000142-35Phase 3Completed
- Sponsor
- Unicancer
- Start
- May 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of abiraterone and prednisone in prostate cancer (PCa) (4 arms), sponsored by Unicancer. Primary endpoints: Overall survival and Castration-resistant prostate cancer progression-free survival. Started May 2013; status: completed.
02
Drugs
abirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-000142-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000142-35.